Similarly, our previous work confirmed high CLC3 expression in cervical cancer and demonstrated that inhibiting ClC-3 expression enhances the sensitivity of cervical cancer to cisplatin [18]. This evidence concerns the gene CLCN3 and cervical carcinoma.